Data presented at AACR Annual Meeting support IMM-1-104 s potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities or. | April 18, 2023
CAMBRIDGE, Mass., April 18, 2023 Immuneering Corporation , a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a. | April 18, 2023
CAMBRIDGE, Mass., April 12, 2023 Immuneering Corporation , a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a. | April 12, 2023
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.